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Abstract
Background: How intestinal epithelial cells interact with the microbiota and how this is regulated at the gene
expression level are critical questions. Smarcad1 is a conserved chromatin remodeling factor with a poorly
understood tissue function. As this factor is highly expressed in the stem and proliferative zones of the intestinal
epithelium, we explore its role in this tissue.
Results: Specific deletion of Smarcad1 in the mouse intestinal epithelium leads to colitis resistance and substantial
changes in gene expression, including a striking increase of expression of several genes linked to innate immunity.
Absence of Smarcad1 leads to changes in chromatin accessibility and significant changes in histone H3K9me3 over
many sites, including genes that are differentially regulated upon Smarcad1 deletion. We identify candidate
members of the gut microbiome that elicit a Smarcad1-dependent colitis response, including members of the
poorly understood TM7 phylum.
Conclusions: Our study sheds light onto the role of the chromatin remodeling machinery in intestinal epithelial
cells in the colitis response and shows how a highly conserved chromatin remodeling factor has a distinct role in
anti-microbial defense. This work highlights the importance of the intestinal epithelium in the colitis response
and the potential of microbial species as pharmacological and probiotic targets in the context of inflammatory
diseases.
Background
The intestinal epithelium is a highly dynamic tissue that
is constantly renewed within a few days, driven by
intestinal stem cells that reside at the base of intestinal
crypts [1, 2]. Intestinal stem cells and their derivatives
express many factors involved in DNA replication, DNA
repair, chromatin packaging, and chromatin remodeling,
including ATP-dependent remodeling factors [3]. The
roles of these factors in genomic and epigenomic stabil-
ity of this tissue are likely of great importance. Under-
standing epithelial biology is complicated by the fact
that this tissue is in close proximity to the gut micro-
biota, which normally is either innocuous or even bene-
ficial to the host, but can become pathogenic. How
intestinal epithelial cells interact with the host immune
system and the microbiota and how this is regulated at
the gene expression level are critical questions.
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ATP-dependent chromatin remodeling factors are
key regulators of many genome functions, including
transcription, DNA repair, and replication [4, 5]. The
Smarcad1/Etl1/Fun30 family of chromatin remodeling
factors is one of the most highly conserved families,
found from fission (Fft1-3) and budding yeast (Fun30)
to mouse (Smarcad1) and human (SMARCAD1), and is
defined by the presence of CUE-domains in addition to
the helicase-like domains [5]. Smarcad1 and its homo-
logs have roles in gene regulation including gene silen-
cing [5–9], heterochromatin maintenance [10, 11],
genome organization [12, 13], and DNA repair [14, 15].
A mutation in a skin-specific isoform of SMARCAD1
in humans causes adermatoglyphia (the loss of finger
prints) and Basan syndrome, which affects skin integrity
[16–18]. SMARCAD1 haploinsufficiency has also been
linked to another skin abnormality, the Huriez syn-
drome [19].
While an early study showed that Smarcad1 is not re-
quired for mouse ES cell viability or proliferation [20],
several studies linked Smarcad1 to stem cell biology
[21–23]. A full non-conditional knockout (KO) of Smar-
cad1 using an exon-trap strategy indicated that while
Smarcad1 was not essential for development, its absence
caused impaired postnatal viability, reduced fertility, and
skeletal dysplasia [20]. In order to explore the role of
Smarcad1 in the mouse further, we generated a new
conditional deletion model and focused on the role of
this gene in the intestinal epithelium. Our analysis shows
that Smarcad1 deletion affects histone modifications in
this tissue, modifying gene expression and intestinal
epithelium-microbiome interactions, which, in turn, im-
pinges on the colitis response in a DSS-induced mouse
model.
Results
A novel Smarcad1 deletion model
We generated a conditional Smarcad1 deletion model
via recombineering to include loxP sites into the mouse
Smarcad1 gene in C57BL/6 J-derived ES cells, using a
cre-recombinase for excision in C57BL/6 J-strain back-
ground animals. We framed exons 12–14 with loxP sites
as these exons code for amino acids critical for ATP
binding of Smarcad1, and thus, their deletion should ab-
rogate enzymatic activity. Furthermore, deletion of these
exons causes a frame shift mutation, leading to the ex-
pression of no functional protein beyond exon 14. In
fact, we found that deletion of these exons led to no
detectable protein in various cell types (Fig. 1). As there
is evidence of a short transcript of SMARCAD1 in
humans, transcribed from an internal start site com-
pared to the full-length transcript [16], we reasoned that
our deletion strategy would insure complete deletion of
any functional Smarcad1.
Smarcad1 is highly expressed in the intestinal crypt, and
its deletion affects epithelial gene expression
RNA-seq, immunohistochemistry, and Western blot
analysis show that Smarcad1 is highly expressed in the
proliferative zones of the intestinal epithelium, both in
the small intestine and colon (Fig. 1a, b, f, Add-
itional file 1: Fig. S1a, b, Additional file 2: Table S1 for
statistical data). In order to explore a role of Smarcad1
in this tissue, we monitored the effects of Villin-cre-
(Vil-cre) mediated [24] tissue-specific Smarcad1 abroga-
tion (Villin-Cre Smarcadfl/fl, further referred as Smar-
cad1-KO) (Fig. 1, Additional file 1: Fig. S1c). Using EdU
pulse labeling, we did not find evidence of a role of
Smarcad1 in regulating dynamics of cell proliferation in
this tissue (Additional file 1: Fig. S1d-f). We did not de-
tect changes in the barrier function by the FITC-dextran
assay (Additional file 1: Fig. S1g).
We performed gene expression profiling by mRNA-
seq from whole small intestinal tissue, extracted colon
crypts, and sorted stem, proliferative, and adult entero-
cytes from the small intestine (Fig. 2a–e, Additional file
1: Fig. S1a, Fig. S4e, Additional files 3: Table S2, Add-
itional file 4: Table S3, Additional file 5: Table S4). We
also performed mRNA-seq on small intestinal organoids
isolated from mice where Smarcad1 had been deleted
and controls, to assess microbiota- and immune system-
independent gene expression (Fig. 2f). The transcrip-
tome analysis in organoids identified the largest number
of differentially expressed genes (DEG, 1407, p < 0.05,
Fig. 2f, Additional file 3: Table S2). In these datasets, we
noted differential expression, mostly upregulation, of
several genes linked to innate immunity and the epithe-
lium interaction with microbiota in KO (Additional file 1:
Fig. S2). These genes include Tlr4, encoding a Toll-like
receptor (intestinal stem cells and organoid datasets);
Itln1, a lectin receptor; defensins Defa22 and Defa26;
Wdfy1 (positively regulates TLR3/4 signaling pathways
[25]); and anti-microbial protein genes Ang4 [26], Reg3b,
and Lyz1 (lysozyme). Mt1 that is significantly upregu-
lated on Smarcad1 deletion plays an important role in
the prevention of colonic mucosal inflammation in the
dextran sodium sulfate (DSS)-induced mouse model of
colitis [27]. Interestingly, Mt1 is not significantly upregu-
lated in the small intestinal organoid culture upon Smar-
cad1-KO, indicating that this upregulation may depend
on some external cue, such as niche, microbiota, or im-
mune cells (Fig. 2, Additional file 1: Fig. S2).
Remarkably, one gene, Bglap3 (also called Bglap-rs1),
whose expression was most enhanced in the small intes-
tine and colon crypt datasets compared to control, was
upregulated in all datasets upon Smarcad1-KO (Add-
itional file 1: Fig. S3a, b). Consistent with increased ex-
pression of Bglap3, we found increased protein levels of
osteocalcin by Western blot (Additional file 1: Fig. S3c-
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e). This gene codes for an osteocalcin protein of a class
that is normally predominantly expressed in bone by os-
teoblasts, regulating calcification, and can also be se-
creted and acts like a hormone, coordinating bone
metabolism with body physiology [28]. The role of
Bglap3 in the gut (if any) is not clear, but one might
speculate that this protein may regulate intestinal cal-
cium uptake. Calcium particles are known to be gener-
ated and secreted in the gut and have been linked to gut
immunity by aiding the delivery of antigens to Peyer’s
patches [29]. We tested this hypothesis by assessing
Ca2+ blood levels, showing that they do not change on
upregulation of osteocalcin in the small intestine upon
Smarcad1-KO, suggesting a separate function of osteo-
calcin in this tissue (Additional file 1: Fig. S3f).
By comparing the various transcriptome analyses (from
colon (CO), sorted stem (ISC), and transit amplifying (TA)
cells as well as adult enterocytes (AE) from small intestine
and small intestine organoids (ORG)), we derived a list of
genes that are upregulated repeatedly in these analyses and,
thus, represents a gene expression hallmark reflecting
Smarcad1 deletion (Fig. 2, Additional file 1: Fig. S2, Add-
itional file 3: Table S2, Additional file 4: Table S3). In
addition to Bglap3 (significant DEG in ISC, AE, ORG, CO),
Mt1 (ISC, TA, AE, CO), and Lyz1 (AE, ORG, CO), these
genes include Bambi (ISC, TA, ORG, CO), Aplp1 (TA, AE,
ORG, CO), Slfn4, Itln1 (TA, AE, ORG), Kirrel2, Tiam1,
Khdc1a, and Mbd1 (ORG, CO). Bambi (BMP and activin
membrane-bound inhibitor) is generally thought to func-
tion as an inhibitory pseudo- (decoy) receptor for TGFβ/
BMP signaling pathways, and thus, its overexpression may
affect inflammatory responses [30–34]. Slfn4 is expressed
from a cluster of genes all expressing Schlafen family mem-
bers. These are AAA-domain containing proteins with
Fig. 1 Smarcad1 localization in the intestinal tract and Vil-cre-mediated KO. a–e Intestinal epithelium localization of Smarcad1 (red) by IF staining
and nuclear counterstaining with DAPI (cyan) shown as maximum intensity projections. Scale bars, 40 μm. a Wild type (WT) small intestinal (SI)
epithelium. b WT colon epithelium. c, d Vil-cre-mediated tissue-specific knockout of Smarcad1 (KO) in SI (c) and colon (d). e No primary antibody
control on WT SI. f, g Representative Western blots of Smarcad1 protein levels in the intestinal tract and H3 loading normalization in WT (f) and
KO (g) samples. Villus and crypt SI samples are shown as anterior, central, and posterior fractions of the SI. Protein size markers [kDa] indicated on
the left. Quantitation of Western blots (n = 3) is shown in Additional file 1: Fig. S1b
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various roles, including in regulating cell proliferation, in
immune system development, function, and interferon re-
sponse, and recently, these proteins have been suggested to
be involved in RNA metabolism [35] (reviewed in [36, 37]).
Aplp1 codes for an amyloid precursor-like protein and is
normally primarily expressed in the nervous system [38].
Kirrel2 codes for a glycoprotein that regulates insulin secre-
tion in beta cells in the pancreas [39]. Tiam1 (T lymphoma
invasion and metastasis 1) codes for a guanine nucleotide
exchange factor (GEF) of Rac1 involved in many signaling
pathways (reviewed in [40]). Khdc1a codes for a transla-
tional repressor involved in endoplasmic reticulum-
dependent apoptosis [41]. In summary, the transcriptomic
analysis indicates that Smarcad1 is involved in repression of
genes linked to innate immunity and inflammation. Fur-
thermore, Smarcad1 appears to control the expression of
genes such as Aplp1 and Bglap3 that are not normally asso-
ciated with intestinal function.
Smarcad1 impacts H3K9me3 over genes and regulatory
elements and controls regulatory element accessibility
Previously, we have shown that Smarcad1 promotes het-
erochromatin features globally in proliferating cells in cul-
ture [10], including histone modifications H3K9me3 and
H3K9me2 as well as HP1 (Heterochromatin Protein 1)
chromatin binding. Depletion of Smarcad1 conversely
Fig. 2 Gene expression changes on Smarcad1-KO. Significantly up/downregulated genes (DESeq2 test with cutoff FDR < 0.1 for a–d and FDR <
0.05 for e, f; for additional data and annotations, see Additional file 3: Table S2, Additional file 4: Table S3) in RNA-seq experiments (n = 3). X-axis:
Smarcad1-KO/WT log (2) fold-enrichment of reads per transcript. Y-axis: -log (10) FDR. High FDR values capped at indicated maximum Y values for
visualization. 0-expression values were set to 0.1 to allow log-plotting of fold changes. a Intestinal stem cells (ISC), FACS-selected by high Lgr5-
GFP signal. b Transit amplifying cells (TA), FACS-selected by low Lgr5-GFP signal. c Adult enterocytes (AE), FACS-selected by EPCAM-positive and
CD31/45-negative signal. d Colon epithelium, FACS-selected by EPCAM-positive and CD31/45-negative signal. e Colon epithelium, isolated as
whole crypt suspension. f Small intestine-derived organoid culture
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promoted global histone acetylation, including H3K9ac
[10]. However, when we examined H3K9me2 and
H3K9me3 levels in tissue extracts from crypts and villi of
the small intestine, as well as colon epithelium extracts,
we did not find global changes of H3K9me2/3 upon dele-
tion of Smarcad1, except for some drop in H3K9me2 in
the small intestinal crypts (Additional file 1: Fig. S4a-c). In
order to test if Smarcad1 has a role in repressive chroma-
tin on a more local level, we performed ChIP-seq for
H3K9me2 and H3K9me3 on chromatin extracts of small
intestinal crypts. Consistent with the notion that
H3K9me3 is linked to gene repression, we found that this
mark is rather low over promoters of highly expressed
genes compared to promoters of lowly expressed genes
(Additional file 1: Fig. S4d). The majority of sites (identi-
fied as MACS-peaks, [42]) with changes of H3K9me3
levels upon Smarcad1-KO showed a depletion of this
mark with only a minor fraction showing increased levels
(Fig. 3a, Additional file 1: Fig. S4f, Additional file 6: Table
S5). We found that deletion of Smarcad1 led to a drop in
H3K9me3 peaks close to and within many genes, suggest-
ing their position over regulatory elements such as pro-
moters and enhancers (Fig. 3c, Additional file 1: Fig. S4f).
We observed that there is a significant association be-
tween changing gene expression upon Smarcad1-KO and
changes in H3K9me3 (Fig. 3d) and that genes that are
misregulated in the small intestine on Smarcad1-KO are
in general associated with decreased H3K9me3 levels
(Fig. 3d, e). Areas that exhibit an increase of H3K9me3 are
usually much broader and, importantly, are found within
the transcribed region of genes (Fig. 3c, Additional file 1:
Fig. S5). Some of the genes that show this type of increase
in H3K9me3 in their gene body show a decrease (e.g.,
Tlr2, Apobec3, Tiam1) or no change (Tcf4, Fat1) in ex-
pression on Smarcad1-KO.
In contrast to H3K9me3, we found that deletion of
Smarcad1 did not appear to affect H3K9me2 in a signifi-
cant manner (Fig. 3b, Additional file 7: Table S6).
We additionally performed H3K9me3 analysis on
colon epithelium by ChIP-seq, as the colon epithelium
functionally differs from the small intestinal epithelium.
Similar to the findings in the small intestine, we found
strong and numerous changes in H3K9me3 on Smar-
cad1-KO, albeit we detected fewer sites with decrease in
H3K9me3 (Fig. 4a–c, Additional file 8: Table S7).
Changes were again linked to changes in gene expres-
sion on Smarcad1-KO, but only significantly over down-
regulated genes that showed an increase in H3K9me3
(Fig. 4c). In contrast to the small intestine, we did not
observe globally a decrease of H3K9me3 over differen-
tially expressed genes and that this mark generally in-
creased over downregulated genes (Fig. 4d). The
observed difference between H3K9me3 over upregulated
genes in the small intestine versus colon epithelium may
relate to the fact that proportionally, we observe more
sites where H3K9me3 decreases in the small intestine
compared to colon epithelium.
To test if deletion of Smarcad1 affects accessibility to
chromatin, we used the ATAC-seq approach on nuclei from
small intestinal crypts [43]. This identified 84 sites that
showed a significant change in accessibility, mostly an in-
crease (76 sites increase, 8 decrease) (Fig. 5a, Additional file 9:
Table S8). On gene level, we also observed a significant link
between loss of accessibility and increase of H3K9me3 close
to or over genes on Smarcad1-KO (Fig. 5b).
In summary, deletion of Smarcad1 leads to specific
changes in histone H3K9me3 and this is linked to
changes in chromatin accessibility and gene expression.
Smarcad1 promotes colitis response
Because the gene expression analysis indicated that
Smarcad1 is involved in regulating multiple genes linked
to innate immunity and inflammatory processes, we
tested the response of the intestine epithelium-specific
knockout mice in the well-established dextran sodium
sulfate (DSS)-induced colitis model, as DSS-mediated
colitis is thought to depend critically on innate immunity
[44]. DSS is a charged polymer that erodes the mucus
layer in the colon when ingested through drinking water,
which, in turn, exposes the colon epithelium directly to
the microbial load of the colon lumen, eliciting an in-
flammatory response [45, 46]. Therefore, this model is
considered especially valid for ulcerative colitis.
It is well established that the DSS colitis response de-
pends on the composition of the microbiota, and it has
been demonstrated that the microbiome of many mouse
facilities lacks complexity [47, 48]. The latter is also true
for the microbiome of the Babraham Institute mouse facil-
ity, as 1% DSS in the drinking water did not elicit a colitis
response as seen by lack of weight loss (Fig. 6a, Add-
itional file 1: Fig. S6a, c, Additional file 10: Table S9).
Therefore, we decided to enrich our mice with micro-
biome from the mouse facility of the University of York
that we knew had a strong colitis response, despite being
specific pathogen free (SPF). We cohoused both sets of
mice (control and intestine-specific Smarcad1-KO mice
from Babraham) and York mice in a ventilated cabinet for
2 weeks, to allow for substantial transfer of microbiota.
We profiled the microbiomes of the control and KO mice
before and after cohousing, as well as donor microbiomes
by 16S RNA amplicon sequencing. This showed no sig-
nificant differences of the control and KO mice before or
after this exposure, indicating that the deletion of Smar-
cad1 does not affect microbiome composition in a major
way (Fig. 7b). In contrast to this, the donor microbiome
was clearly distinct and more complex from the recipient
microbiome (Fig. 7a–c, Additional file 1: Fig. S8). Further-
more, we detected transfer of specific microbial species
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Fig. 3 H3K9me2/3 changes linked to Smarcad1-KO in the small intestine. EdgeR analysis (p < 0.05) of read counts over H3K9me3 (a) or H3K9me2
(b) peaks reveals regions with significant alterations in these histone marks on deletion of Smarcad1 in the small intestinal epithelium by Vil-cre
(KO). Datasets shown as averaged from 3 replicates (for additional data and annotations, see Additional file 6: Tables S5, Additional file 7: Table
S6). c Examples of H3K9me3 changes over selected regions. The top annotation tracks indicate genes, transcripts, and H3K9me3 MACS peaks.
Read counts are shown in linear scale, color coded. Chromosomal positions and window sizes in kbp are indicated. d Link between changes in
gene expression and changes in H3K9me3. Venn diagrams showing the distribution of differentially expressed genes (DEG) in small intestine
organoids on Smarcad1-KO (see Additional file 1: Fig. S2a, Additional file 3: Table S2) and genes from small intestinal crypts with differential
H3K9me3 MACS peaks within ± 5 kbp of the gene (EdgeR p < 0.05, see Additional file 6: Table S5). There is a significant overlap between genes
with increased expression and decreased H3K9me3 (p = 0.00017, chi-square, number of expressed genes 25,965, Additional file 2: Table S1). The
Venn diagrams are not drawn to scale. e Normalized H3K9me3 ChIP-seq read count quantitation over MACS peaks, log2 transformed, adjusted
for matching distributions in SeqMonk. Separate quantitations over all annotated genes (32,029 genes) and ± 5 kbp up- and downstream of
genes with up- and downregulated expression in small intestinal organoids on Smarcad1-KO (1420 genes, see Additional file 1, Fig. S2,
Additional file 3: Table S2). p values from an unpaired two-tailed t test with Welch’s correction are indicated (n = 3). Error bars indicate the
standard error of the mean (SEM) of read count quantitation of each biological replicate
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(Fig. 7c, Additional file 1: Fig. S8c-g). Our analysis high-
lights at the phylum level the significant transfer of TM7
(Fig. 7c, d, see the “Discussion” section). At the family
level, we see transfer of Dehalobacteriaceae and at the
species level Ruminococcus gnavus. This analysis shows
also significant loss of class Erysipelotrichi on transfer in
the recipient animals.
Next, we repeated the colitis experiments with the
microbiome-enriched control and Smarcad1-KO mice.
We found that the microbiome-enriched control mice
reacted with a clear colitis response to DSS, developing
soft stool and, thereafter, losing significant amount of
weight. Remarkably, the intestine-specific Smarcad1-KO
mice did not exhibit this phenotype (Fig. 6b, Add-
itional file 1: Fig. S6b, d-f, Additional file 10: Table S9).
It is known that DSS-mediated colitis is associated
with focal invasion of neutrophils and monocytes into
the colon epithelium [44]. We did observe infiltration of
these cell types in the DSS-treated wild type mice, as
shown by anti-myeloperoxidase (MPO) staining (Fig. 6c,
d, Additional file 1: Fig. S7). Consistent with a reduced
colitis response, this occurred to a lesser extent in the
Smarcad1-KO mice (Fig. 6c, d, Additional file 1: Fig. S7).
To explore this on a molecular level, we extracted
mRNA from colon tissue of untreated mice and from
mice after DSS treatment and performed transcriptome
analysis by RNA-seq (Additional file 1: Fig. S9, Add-
itional file 11: Table S10, Additional file 12: Table S11).
We identified 3261 DEG on colitis induction in WT
(wild type) mice (DESeq2 test, cutoff false discovery rate
(FDR) < 0.05, Additional file 13: Table S12), and gene
ontology analysis confirms a strong link of these genes
to inflammatory responses (Additional file 1: Fig. S6g).
Most of these genes respond in the similar way to colitis
Fig. 4 H3K9me3 changes linked to Smarcad1-KO in the colon. a EdgeR analysis (p < 0.05) of read counts over H3K9me3 peaks reveals regions
with significant alterations in this histone mark on deletion of Smarcad1 in the small intestinal epithelium by Vil-cre (KO). Datasets shown as
averaged from 3 replicates (for additional data and annotations, see Additional file 8: Table S7). b Examples of H3K9me3 changes over Bach1. The
top annotation tracks indicate the gene, exons, and H3K9me3 MACS peaks. Read counts are shown in linear scale, color coded. Chromosomal
position and length in kbp are indicated. c Link between changes in gene expression and changes in H3K9me3. Venn diagrams showing the
distribution of differentially expressed genes (DEG) in the colon on Smarcad1-KO (93 DEG in either whole crypt or sorted epithelium datasets, see
Additional file 1: Fig. S2b, Additional file 4: Table S3) and genes with differential H3K9me3 MACS peaks within ± 5 kbp of the gene (EdgeR p <
0.05, see Additional file 8: Table S7). There is a statistically significant overlap between genes with decreased expression and increased H3K9me3
(p = 0.05, chi-square, number of expressed genes 25,965, Additional file 2: Table S1). The Venn diagrams are not drawn to scale. d Normalized
H3K9me3 ChIP-seq read count quantitation over MACS peaks, log2 transformed, adjusted for matching distributions in SeqMonk. Separate
quantitations over all annotated genes (32,029 genes) and ± 5 kbp up- and downstream of genes with up- and downregulated expression in the
colon on Smarcad1-KO (93 DEG in either whole crypt or sorted epithelium datasets, see Additional file 1: Fig. S2b, Additional file 4: Table S3). p
values from an unpaired two-tailed t test with Welch’s correction are indicated (n = 3). Error bars indicate the SEM of read count quantitation of
each biological replicate
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on Smarcad1-KO (Fig. 8a). However, a subset of genes
shows incomplete upregulation on colitis induction in
Smarcad1-KO mice. We identified these genes as cluster
A (572 genes, see Additional file 14: Table S13). Upon
gene ontology analysis comparing cluster A to the gene
list upregulated on colitis in WT (see annotation in
Additional file 13: Table S12), we identified a number of
enriched terms (g:profiler, full parameters and enriched
terms: Additional file 19: Table S18). The most biologic-
ally meaningful terms, shown in Fig. 8c, indicate poten-
tially Smarcad1-dependent pathways in the complex
colitis response.
A finer resolved hierarchical clustering was performed
to detect genes with complete or near complete loss of ex-
pression changes on colitis in Smarcad1-KO. These genes
were identified as clusters 1/2 (normally upregulated on
colitis in WT) and 3/4 (normally downregulated on col-
itis), with a total of 84 genes (Fig. 8b and listed with rele-
vant annotations in Additional file 15: Table S14). Gene
ontology (GO) analysis of clusters 3/4 did not yield any
enriched annotations, probably due to the small size of
these clusters (g:profiler, cutoff p < 0.05, Additional file 20:
Table S19). GO analysis of cluster 2, containing genes
with complete loss of Smarcad1-dependent upregulation
on colitis, yielded several enrichment terms (Fig. 8d, Add-
itional file 17: Table S16, Additional file 18: Table S17).
This includes the significantly enriched group of extracel-
lular protease encoding genes (also indicated in Fig. 8b).
Stainings for Adamts1, Adamts5, and Bmp1 showed simi-
lar distribution patterns as the MPO-staining, indicating
that these proteases are contributed not by the colon
epithelium, but by invading neutrophils/monocytes on
colitis induction (Additional file 1: Fig. S7). The GO ana-
lysis also highlights a potential role of Smarcad1 in the IL-
17 pathway in colitis. The transcriptome-based analysis
of the colitis response illustrated the upregulation or
shutdown of expression of many genes upon DSS treat-
ment and shows that this transcriptional response was
subdued for many genes in the intestine-specific Smar-
cad1-KO mice.
Discussion
Previous work has indicated an important role of Smar-
cad1 and its homologs in the maintenance of heterochro-
matin, especially during or following the DNA replication
process [10, 11] and the silencing of endogenous retrovi-
ruses in embryonic stem cells [65], but the importance of
this role in a tissue context was not clear. We found that
this factor is highly expressed in the crypt of the small in-
testine, which is the zone of cell proliferation, consistent
with a role during chromatin replication. Here, we did not
find evidence that Smarcad1 affected global H3K9me3
levels, as we have previously shown in cultured cells. How-
ever, on genome-wide analysis, we found significant
changes of H3K9me3 upon Smarcad1-KO and many of
these changes are a loss of H3K9me3 over a defined re-
gion, close to or in the vicinity of genes, including many
upregulated genes. We found a significant link between
these changes and alterations in gene expression, espe-
cially in the small intestinal epithelium, and several of the
affected genes are linked to innate immunity processes.
Fig. 5 Smarcad1-KO changes chromatin accessibility in the small intestine. a The scatter plot of normalized read counts over ATAC-seq MACS
peaks shows 84 differentially accessible regions (blue and red dots) as identified by EdgeR (padjust < 0.05, n = 3) on deletion of Smarcad1 in the
small intestinal epithelium (KO) compared to control (WT). For additional data and annotations, see Additional file 9: Table S8. b Comparison
between genes with differential accessibility and genes with differential H3K9-trimethylation on Smarcad1-KO (ATAC-seq and ChIP-seq MACS
peaks, annotation with closest gene ± 5 kbp, n = 3, see Additional file 6: Table S5, Additional file 9: Table S8). Of the genes that show increased
accessibility and decreased H3K9me3, Clec2g and Lyz1 are overexpressed on deletion of Smarcad1 in the small intestinal epithelium (KO). There
was no overlap between genes with increased accessibility and increased H3K9me3 nor with genes with decreased accessibility and decreased
H3K9me3. The Venn diagrams are not drawn to scale
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We observed a notable difference in the number of sites
where H3K9me3 decreases between the small intestine and
colon epithelia, possibly linked to the histological differences
in the cells we isolated for the analysis. We isolated crypts of
both small intestine and colon tissue for the ChIP-seq ana-
lysis. Colon crypts contain proportionally more differenti-
ated cells compared to small intestine crypts. Future analysis
should unravel the role of Smarcad1 in H3K9me3 establish-
ment and maintenance during differentiation.
Unlike the study from Sachs et al. that document Smar-
cad1 binding by ChIP-seq [65], we have not been able to
produce a Smarcad1 ChIP-seq profile employing same
antibodies and protocols. This may relate to the much
lower expression of Smarcad1 in somatic type cells com-
pared to embryonic stem cells, as shown by the Sachs
et al. study. Furthermore, the predominant localization of
Smarcad1 in the stem and proliferative compartment of
the intestinal epithelium is consistent with a global rather
Fig. 6 Smarcad1-dependent Colitis susceptibility. a, b 1% DSS-induced colitis phenotype in WT and Smarcad1-KO animals with initial (non-
enriched) microbiota (a) and enriched microbiota (b, 2 independent experiments shown: b-1/b-2). Experiments a and b-1 were terminated after
15 days (n = 5 for WT/KO), and experiment b-2 after 14 days with one mouse culled after 10 days due to extensive weight loss (n = 8 for WT, n = 6
for KO). SEM indicated by error bars. Indicated p values determined by 2-way ANOVA with Holm-Sidak’s multiple comparisons test, performed
separately for each experiment. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Full statistical results are listed in Additional file 2: Table S1. c, d
Intestinal colon epithelium localization (c) and quantitation (d) of MPO-positive cells (green, neutrophil/lymphocyte-marker) by IF staining and
nuclear counterstaining with DAPI (blue) shown as maximum intensity projections. The 14-day colitis induction with enriched microbiota.
Representative replicates, full image set, and negative staining controls shown in Additional file 1: Fig. S7. Scale bars, 40 μm. WT, wild type; KO, Vil-
cre-mediated tissue-specific knockout of Smarcad1. d Epithelial and sub-epithelial number of MPO-positive cells per imaged area, quantified from
the full image set shown in Additional file 1: Fig. S7 (3 biological replicates for WT/KO, 2–4 technical replicates each). Indicated p values
determined by 2-way ANOVA with Holm-Sidak’s multiple comparisons test, performed separately for each epithelial/sub-epithelial localization. Full
statistical results are listed in Additional file 2: Table S1
Kazakevych et al. Genome Biology           (2020) 21:64 Page 9 of 20
Fig. 7 Microbiome and Smarcad1-dependent colitis susceptibility. a Alpha-diversity plots before and after microbiome enrichment, as well as
donor microbiota, shown as observed species number (left) and chao-quantitation (right). Outliers (*) were identified with the ROUT algorithm in
GraphPad Prism with the Q-cutoff set to 0.1%. Outliers were omitted for the following statistical analysis by 1-way ANOVA with Holm-Sidak’s
multiple comparison test, p values indicated. SEM indicated by error bars. Full statistical results are listed in Additional file 2: Table S1. b Beta-
diversity plot based on unweighted unifrac diversity distance (phylogenetic distance analysis of detected OTUs). Outliers previously detected
based on alpha-diversity are indicated in gray. c Heat map of log10 transformed OTU abundance at the phylum level identifies TM7 as a phylum
transferred on microbiota enrichment; see Additional file 1: Fig. S8 for other phylogenetic levels. Phylogenetic terms significantly different
between initial and enriched microbiota (FDR < 0.1, Wilcoxon test, n = 20, outliers not excluded) are indicated with FDR and fold changes
(enriched/initial). Terms shown in d are underlined. d Taxa substantially changed on microbiota enrichment (> 2-fold change, Wilcoxon test FDR
< 0.05, n = 20, outliers not excluded) are indicated with FDR and fold changes between enriched and initial microbiota groups. Disease
associations shown represent one or more previous studies in feces/colon biopsies from humans or mouse [49–64]. Where the cited studies have
shown contradicting interactions, the predominant interactions are indicated
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than locus-specific role, e.g., maintenance of heterochro-
matin through replication [10].
Interestingly, Smarcad1-KO led to an increase of
H3K9me3 over broader regions within the coding re-
gions of a number of genes, and in some cases, this was
linked to decreased expression. It is possible that Smar-
cad1 has a role during transcription elongation of a gene
subset. A role in transcription elongation has been sug-
gested for the fission yeast Smarcad1 homolog Fft3 [66].
However, as we find such changes only in select genes,
this activity appears to be gene specific.
We only observed few changes in gene accessibility by
our ATAC-seq approach. While this may be due to tech-
nical limitations, it might reflect the biology of the intes-
tinal epithelium. In this context, it is interesting that a
previous study found that changes in gene expression
during intestinal cell maturation do not involve dramatic
changes in chromatin accessibility [67].
We found that intestine epithelium-specific Smarcad1-
KO protects the mice from DSS-induced colitis, reducing
the response in terms of weight loss, disease activity index,
MPO+ cell recruitment, and gene expression response.
Fig. 8 Smarcad1-dependent transcription response. Changes of gene expression on DSS-induced colitis in microbiota-enriched animals. a WT/
Smarcad1-KO heat map of all differentially expressed genes (DEG) between control and DSS-induced colitis in colon epithelium samples (WT-
colitis vs. WT-control, DESeq2, FDR < 0.05, Additional file 13: Table S12). Cluster A (Additional file 14: Table S13) contains genes not upregulated on
colitis in Smarcad1-KO colon to the same extent as in WT. b DEG showing a diminished colitis response on Smarcad1 presence. Classified in 4
clusters. A full list of Smarcad1-dependent response genes in the indicated clusters is attached with functional annotations in Additional file 15:
Table S14. The enriched genes annotated as extracellular proteases are labeled. c, d Enrichment of selected terms detected by gene ontology
analysis. BP, biological process; CC, cellular component; MF, molecular function; KEGG, KEGG biological pathways; REA, reactome. Dashed line
indicates significance threshold corrected p = 0.05. Gene number annotated in the cluster with a specific term is indicated next to each bar. c
Cluster A (Additional file 14: Table S13) vs. genes upregulated on colitis in WT (Additional file 13: Table S12, marked UP). d Cluster 2 versus genes
expressed in the colon (Additional file 16: Table S15) shown in gray and versus genes upregulated on colitis in WT (Additional file 13: Table S12)
shown in black. Full gene ontology enrichment analysis is listed in Additional file 17: Table S16 and Additional file 18: Table S17
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This observation is striking, as a majority of gene deletions
would be expected to lead to increased colitis susceptibil-
ity. However, there is precedence for such an observation.
For example, monoallelic deletion of the non-muscle-
myosin-II (NMII) heavy chain My9 gene alleviates DSS-
induced colon crypt damage and colitis, possibly by
promoting intestinal stem cell turnover [68]. We did not
find evidence that deletion of Smarcad1 affects intestinal
cell turnover or epithelial barrier function, but rather, we
found that it leads to changes in gene expression that are
consistent with a protective effect. In the steady-state con-
dition, we found that Smarcad1-KO promoted expression
of several genes linked to innate immunity, such as Toll-
like receptor Tlr4, anti-bacterial peptides, and other fac-
tors controlling inflammatory responses such as Lyz1.
One gene that is highly overexpressed upon Smarcad1-
KO in steady state and colitis is Mt1, coding for metallo-
thionein. Metallothionein has been reported to protect
against colitis in mouse models, but its role in this process
requires further investigation [27, 69–73]. Another gene
that is upregulated upon Smarcad1 deletion codes for
Bambi. Bambi is a TGF-beta decoy receptor that dampens
or blocks the activity of this cytokine and thus controls in-
flammatory responses [30, 74]. TGF-beta is involved in in-
flammatory responses, including in colitis [75]. This
suggests that Smarcad1 is normally involved in a pathway
that controls an innate immunity response, and upon its
deletion, the intestinal epithelium may already be primed
to deal with a microbial challenge during the DSS treat-
ment. On DSS treatment, the deletion of Smarcad1 leads
to specific changes in gene expression consistent with the
reduced colitis response. Together, our data suggest that
this chromatin remodeling factor orchestrates the expres-
sion of genes involved in an inflammatory response in the
gut. As we made these observations with an intestinal
epithelium-specific deletion of Smarcad1, our observa-
tions underscore the importance of the intestinal epithelial
tissue and innate immunity-linked processes in mediating
a colitis response.
We identified several members of the gut microbiome
that are responsible for a robust colitis response in a
Smarcad1-dependent way. These are candidates for pro-
moting colitis disease progression during the DSS treat-
ment, requiring the presence of Smarcad1 in the
intestinal epithelium. Interestingly, these are members of
a healthy SPF microbiome and are not normally associ-
ated with disease without additional challenge. Standing
out among these in terms of consistency and fold in-
crease are members of the TM7 (also called Saccharibac-
teria) phylum, recently described and poorly understood
Gram-positive bacteria. Interestingly, the one TM7
member that has been cultivated so far is an epibiont
and parasite on another bacterial species, affecting the
hosts’ interaction with the human immune system [76].
A potential link between TM7 strains and Crohn’s dis-
ease has been previously described [49]. TM7 levels are
regulated by the inflammasome [77] and have been
linked to inflammatory activity of the microbiome in
aged mice [78] and changes in the mucus layer barrier
function of the distal colon [79]. Another increased spe-
cies is Ruminococcus gnavus, a member of the class Clos-
tridia. Increased levels of R. gnavus have been linked to
intestinal inflammatory diseases [50–53, 80]. R. gnavus is
a mucolytic bacterium which alters mucus protective
function [54, 81]. We also see a loss of members of the
class Erysipelotrichi, which promote barrier function of
the colon epithelium [79]. Overall, the changes we detect
in our enriched microbiota are consistent with the
greater colitogenic effect. Whether it is a single species,
such as TM7, that drives this effect or the combination
of several remains to be elucidated.
Conclusions
Our study demonstrates the critical role of chromatin
dynamics in intestinal epithelial cells in host-
microbiome interactions, regulating the colitis response.
We uncover the role of a highly conserved chromatin re-
modeling factor in this process and show that it operates
by affecting the repressive H3K9me3 histone modifica-
tion over genes that are involved. In addition to Smar-
cad1, we identify candidate bacterial species crucial for
the phenotype severity of colitis, highlighting their po-
tential as targets for pharmacological and probiotic
treatment of intestinal inflammatory diseases.
Methods
Mice
All mice were C57BL/6 background, males, and kept in
specific opportunistic pathogen free (SOPF) conditions
at the Babraham Institute transgenic facility and fed
CRM (P) VP diet (Special Diet Services) ad libitum. Ani-
mals were sacrificed by CO2 asphyxiation followed by
cervical dislocation.
Conditional deletion of Smarcad1
We generated mice with loxP sites integrated in the in-
trons between exons 11 and 12 and between exons 14 and
15 of Smarcad1 through recombineering [82]. Details re-
garding the construction of a Smarcad1 targeting vector
and generating transgenic mice are available on request.
BAC clone RP23-331E23, which completely spans the
Smarcad1 gene, constructed by the laboratory of Pieter de
Jong at Roswell Park Cancer Institute was obtained from
MRC Geneservice. BAC DNA was electroporated into E.
coli EL350. Positive clones were selected with 12.5 μg/ml
chloramphenicol. The construction of retrieval vector was
essentially as described in [82]. In brief, two pairs of PCR
primers denoted as A, B and Y, Z were designed. These
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amplify ~ 500 bp segments located 14.6 kbp apart within
the Smarcad1 gene. Separate PCRs were carried out using
A + B and Y + Z oligos on BAC 331E23. The purified AB
product was cleaved with Not1/HindIII and the YZ prod-
uct with HindIII/Spe1. After digestion, AB and YZ frag-
ments were ligated into Not1/Spe1 cut vector PL253 and
cloned in E. coli. The retrieval plasmid was linearized with
HindIII and transformed into EL350 cells containing the
BAC, and cells containing the desired recombinant mol-
ecule were selected on ampicillin. This resulted in cells
where BAC DNA was successfully retrieved into PL253,
called pGRSB (Gap Repaired Smarcad BAC).
In order to introduce a floxed Neo cassette, the Neo
cassette in PL452 was amplified by PCR with 300 bp
arms. Two pairs of PCR primers were used: CD and EF.
Primers E and F contained BamHI and NotI sites in
their respective tails; C and D contained SalI and EcoRI
sites. PCR product EF was purified, digested with
BamH1/NotI, and ligated into BamHI/NotI cut PL452.
Transformed E. coli were selected on 50 μg/ml ampicil-
lin, and the obtained plasmid, termed PL452EF, was
digested with SalI/EcoRI and ligated to SalI/EcoRI
digested PCR product CD. The resulting plasmid was
termed PL452CDEF. Next, the Neo cassette with two
flanking regions of Smarcad1 was isolated by digestion
of PL452CDEF with SalI/NotI. This yielded a 2.6-Kb
fragment which was purified and recombined into the
Gap-retrieved BAC. The Neo cassette was electroporated
and recombined in EL350 cells containing the retrieved
BAC, and selection was with kanamycin resulting in
plasmid pGRSB5’Neo. The Neo cassette was now excised
by electroporation into cells with 0.1% arabinose-
induced Cre recombinase and selected on 50 μg/ml
ampicillin or 12.5 μg/ml kanamycin. Plasmid from col-
onies which grew on ampicillin but not kanamycin was
digested with BamHI and PCR amplified with oligos de-
rived from PL452 sequences flanking the SalI and NotI
sites, respectively. Two clones, termed pGRSB5’loxP9
and pGRSB5’loxP11, were confirmed by sequencing to
contain a single loxP site integrated at the correct loca-
tion. Next, the downstream Neo cassette, derived from
PL451 (containing FRT–PGK–EM7–NeobpA–FRT–
loxP), was assembled. PCR primers G, H, I, and J con-
taining recognition sites for SalI, HindII, BamHI, and
NotI in their respective tails were synthesized. PCR
product GH was digested with SalI/EcoRI and then li-
gated into SalI/EcoRI digested PL451 and transformed
into E. coli Top10, digested with BamHI/NotI, and li-
gated to BamHI/NotI cut PCR product IJ. Ligations were
transformed into Top10 cells yielding plasmid PL451-
GHIJ. PL451-GHIJ was digested with NotI/SalI. The in-
sert, comprising the PL451 Neo cassette flanked by
Smarcad1 fragment GH and IJ, was now recombined
into the targeting vectors pGRSB5’loxP 9 and 11,
containing the upstream (left hand) loxP site with 50 μg/
ml ampicillin selection. GH-Neo-IJ insert was electropo-
rated into induced EL350 cells with kanamycin selection
(12.5 μg/ml). The resulting plasmids PGRSB5’loxP3’Neo
were re-transformed into NovaBlue with kanamycin se-
lection (12.5 μg/ml). Digestion with BamH1 and sequen-
cing using G and J oligos confirmed correct assembly of
the final construct.
One hundred micrograms of pGRSB5’loxP3’neo was
linearized with NotI and transformed into Bruce4 ES
cells using electroporation by the Babraham Institute
Gene Targeting facility. We mapped correct integration
of the targeting construct by Southern blotting after di-
gestion of genomic DNA with BamHI. We confirmed
that the four correctly targeted clones contained a single
integration of the targeting cassette, by cleaving DNAs
with BglII followed by gel electrophoresis and Southern
blotting. Two of the four positive ES cell clones, C: D3
and C: E6, were injected into C57BL/6 blastocysts. This
gave rise to chimeras and ultimately two mouse lines
where Smarcad1 had been targeted: CD3 and CE6. We
found that on intestinal deletion of the exons by Vil-cre,
both mouse lines overexpressed Bglap3. We decided to
use the CE6 line for all further studies.
The Vil-cre allele was introduced through the Tg (Vil1-
cre)997Gum mouse [24] (JAX stock #004586, The Jackson
Laboratory). Genotyping PCR protocols are available on
request. To isolate small intestinal stem cells, we crossed
in the Lgr5-EGFP-IRES-creERT2 “knock-in” allele (Lgr5-
EGFP-IRES-creERT2 mice, C57BL/6 J background, ob-
tained from Jackson Laboratory [83]).
DSS-induced colitis
Within each experiment, the cohorts were age matched
and, as much as possible, litter matched. The order of sam-
ples from cohorts was mixed on collection. No samples
were excluded from the analysis. No blinding was con-
ducted. Mice were acclimatized to the experimental setup
in ventilated cabinets (scantainers) 2 weeks prior to DSS ad-
ministration. Enriched microbiota was provided from this
time point by bedding transfer and co-ventilation with the
donor C57BL/6 females obtained from the University of
York SPF facility. One percent dextran sulfate sodium salt
(Sigma Aldrich 42867) was continuously administered with
drinking water and exchanged every 3 days. Animal health
status and weight were recorded daily.
Barrier permeability assay
FITC-dextran flux measurements were performed as de-
scribed [84]. Blood was collected from tail veins.
Epithelial cell isolation for RNA-seq and ChIP-seq
Small intestines were dissected as described [85]. Colons
were dissected by the same protocol with extended PBS-
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EDTA incubation (30 min) and crypt shaking extraction
(5 min). Whole crypt epithelium RNA was isolated and
ChIP-material processed at this stage. Single cell mater-
ial was derived from intestinal crypts by digestion with
Dispase II (Sigma D4693, 0.05 mg/ml), DNase (Qiagen
79254, 20 Kunitz U/ml), and Collagenase (Sigma C7657,
0.15 mg/ml), while villus single cells were derived with-
out digestion, by vigorous pipetting. Small intestinal vil-
lus- and colon crypt-derived cells were stained in 2%
fetal bovine serum (FBS)/phosphate buffered saline
(PBS) with 1:200 APC-conjugated Epcam antibody
(CD326, eBioscience 17-5791-82), 1:1000 AF488-
conjugated CD45 antibody (Biolegend 103122), and 1:
1000 AF488-conjugated CD31 antibody (Biolegend
102414) for 15 min at room temperature, washed 3 times
and resuspended in 2% FBS/PBS with 3.2 μg/ml ROCK-
inhibitor (Y-27632, Sigma). All cell preparations were
stained with 4′,6-diamidino-2-phenylindole (DAPI) prior
to sorting. Epcamhigh CD31− CD45− DAPI− cells were
sorted on BD Aria III SORP cell sorter, 100 μM nozzle.
RNA from ISC (GFPhigh DAPI−) and transit amplifying
cells (TA, GFPmedium DAPI−) was isolated from single
cell crypt suspensions of Lgr5-GFP+mice and processed
as above except the antibody staining step (Add-
itional file 1: Fig. S10). 1000–80,000 ISC, 1000–135,000
TA, 100,000 AE, and 75,000–100,000 colon epithelial
cells (CO) were sorted per sample into RLT buffer for
subsequent RNA isolation with the RNeasy Micro kit
(Qiagen 74004) with on-column DNA digestion.
RNA-seq ISC, TA, AE, and CO
Libraries were generated from 2 to 10 ng total RNA with
RNA integrity number (RIN) 6.2–9.1 as input according to
NEB Ultra II Directional RNA Library Preparation Kit for
Illumina (E7760), Poly(A) mRNA magnetic isolation mod-
ule (E7490), and multiplex oligos (NEB E7335, E7500) man-
uals with the following modifications: RNA was fragmented
for 20min, adaptor stock was diluted 150-fold, and 15 cy-
cles were used in the PCR-amplification step. SPRI select
beads were substituted with Seramag Speedbeads (Thermo
scientific 65152105050250) for size selection steps. Seramag
beads were washed with TE buffer and resuspended in 50
volumes of PEG 8000 (Sigma 1546605) with 2.5M NaCl,
10mM Tris-Cl pH 8.0, 1mM EDTA, and 0.05% Tween 20.
PEG 8000 amounts used were 10 and 12% final PEG con-
centrations on sample addition. Size selection steps were
performed at room temperature, adding the sample topped
up to 100 μl with nuclease-free water to 80 μl of bead sus-
pension, followed by resuspension by pipetting, incubation
for 10min, and magnetic pelleting. After removal of super-
natant (SN), the beads were washed twice with 80% ethanol
and moderately dried before elution in TE buffer. The size
selection after second strand DNA synthesis was performed
with 12% final PEG concentration, and the remaining size
selections with 10% PEG. After PCR amplification, the size
selection was performed twice (10% PEG). Libraries were
sequenced on an Illumina HiSeq2500 as HiSeq 50 bp
single-end reads.
Colon epithelium isolation for RNA-seq after DSS
treatment or enrichment of microbiota
The central 1/3 of the colon was cut open longitudinally,
washed in PBS to remove feces, and snap frozen in li-
quid nitrogen. Twenty-five to 100 mg of frozen tissue
was ground to powder with dry ice. After addition of 1
ml TRIzol, the sample was collected and incubated 5
min at RT. Two hundred microliters of chloroform was
added prior vortexing and centrifugation 20min at 16,
000×g, 4 °C. The upper phase was transferred to 500 μl
isopropanol, vortexed and incubated 15min at RT be-
fore centrifuging 10min at 16,000 x g, 4 °C. To deplete
DSS, after discarding the SN, LiCl-precipitation was per-
formed [86] at 4 °C by dissolving the pellet in 120 μl
H2O and addition of 80 μl 2 M LiCl and 2 h incubation
prior to centrifugation for 30 min at 14,000 x g. LiCl-
precipitation was repeated once more and the pellet dis-
solved in 200 μl H2O. Next, the RNA was precipitated
substituting LiCl with 20 μl 3 M NaAc, pH 5.2 and
400 μl 100% EtOH, with 30 min incubation at − 20 °C.
After centrifugation, the pellet was washed once in 70%
EtOH before resuspending in cold H2O.
Whole tissue small intestine isolation for RNA-seq
RNA from small intestine whole tissue was isolated as
described above for whole colon tissue, without LiCl
precipitation steps.
RNA-seq colon epithelium after DSS treatment and
enrichment of microbiota
At least 1 μg total RNA (RIN 7.2–8.5) per sample were
sequenced by BGI Hong Kong on the BGISEQ-500 plat-
form as 100 bp paired-end reads, yielding fastq files fil-
tered for low-quality, N-rich, or adaptor-polluted reads.
Western blotting
Small intestinal crypts and villi, as well as colonic epithe-
lium, were extracted as described above including the
shaking extraction. The epithelium was then pelleted 10
min at 500×g, resuspended in Laemmli 2x lysis buffer sup-
plemented with 5% Beta-Mercaptoethanol and boiled for
1min. Samples were briefly sonicated to reduce viscosity.
Anti-Smarcad1 (Sigma HPA016737, 0.3 μg/ml), anti-
H3 (Abcam 1791, 0.025 μg/ml), anti-Osteocalcin (Santa-
Cruz 365797, 4 μg/ml), anti-H3K9me2 (Abcam 1220,
0.18 μg/ml), and anti-H3K9me3 (Abcam 8898, 0.2 μg/
ml) antibodies were used for Western blot with BSA
blocking, Tris-buffered saline (TBS) 0.05% Tween-20
(TBS-T) washing buffer, and enhanced
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chemiluminescence (ECL) detected on x-ray film. Protein
ladder was from Thermo Scientific #26616. Uncropped
Western blots are shown in Additional file 1: Fig. S11.
Immunofluorescent staining
Smarcad1 immunofluorescent (IF) staining was performed
as described in [87] with the following antibodies: primary
anti-Smarcad1 (Sigma-Aldrich HPA016737, 1.5 μg/ml)
and secondary anti-rabbit AlexaFluor 568 (Invitrogen
A11036, 2 μg/ml). MPO, Adamts1, Adamts5, and Bmp1
IF stainings were performed, and MPO-positive cells
quantified as described in [88] with the following anti-
bodies: primary anti-MPO (R&D AF3667, 5 μg/ml), pri-
mary anti-Adamts1 (Abcam ab39194, 1 μg/ml), primary
anti-Adamts5 (Abcam ab246975, 0.5 μg/ml), primary anti-
Bmp1 (Abcam ab38953, 2 μg/ml), and secondary anti-goat
AlexaFluor 488 (Invitrogen A11055, 10 μg/ml) and anti-
rabbit AlexaFluor 568 (Invitrogen A11036, 20 μg/ml).
Confocal imaging was performed on a Zeiss 780 confocal
microscope with a × 20 Plan Apo air objective at optimal
resolution settings with 2× line averaging. Contrast en-
hancement with minor pixel saturation was performed
with FIJI [89]. MPO-staining was performed as 2–4 tech-
nical replicates (different intestinal positions within the
same sample) that were measured and averaged per sam-
ple. The following are the average total imaged per sam-
ple: 0.47mm2 epithelial area and 0.30mm2 sub-epithelial
area. Imaging areas were measured with FIJI, and positive
cells counted manually after background correction.
5-Ethynyl-2′-deoxyuridine (EdU) labeling
One hundred micrograms of EdU (Invitrogen, A10044) in
200 μl PBS per mouse was injected intraperitoneally (ani-
mal weight 29–36 g). Mice were sacrificed and processed
after 24 h. The intestine was extracted, flushed with PBS
at 4 °C, and fixed in 4% formaldehyde (FA)/PBS solution
for 24 h at 4 °C. After cryopreservation in 30% sucrose for
24 h at 4 °C, the samples were frozen in Cryomatrix (Ther-
moFisher 6769006). Frozen blocks were cut with the Leica
CM1860 cryotome to 10 μm sections onto Superfrost Plus
slides (ThermoFisher 4951PLUS4). Before staining, slides
were dried for 15min at room temperature and refixed
with 4% FA/PBS. Samples were permeabilized in 1%
TritonX-100/PBS at RT for 20min, washed 3× for 5min
in PBS, and incubated in blocking buffer (1% TritonX-
100, 5% FBS, 2% BSA) for > 1 h. Click-iT reaction was per-
formed according to the manufacturer’s instructions (Life
Technologies, Click-iT Plus EdU imaging kit C10637). 0.5
ml Click-iT reaction mix were incubated on the sample
for 30min at RT protected from light and washed with 3%
BSA/PBS before mounting with Vectashield (Vector, H-
1200, with DAPI). Sections were imaged with the Zeiss780
confocal microscope, × 20 air objective at optimal reso-
lution settings and 2× line averaging. FIJI [89] and Excel
were used to analyze EdU signal distance to crypt bottom
(see Additional file 24: Table S23, Additional file 25:
Protocol S1).
Small intestinal organoid culture and RNA-seq on
organoids
Small intestinal crypts were derived from mice where Smar-
cad1 had been deleted in oocyte development using ZP3-
cre and control litter mates, using a slightly modified
protocol as described [87]. Isolation of small intestinal
crypts for organoid culture was performed using a modified
version of a previously described protocol [90]. Small intes-
tines were collected and opened longitudinally. The villus
content was removed by scraping the intestine with a
coverslip and by shaking the samples vigorously in cold
DPBS (Dulbecco’s phosphate-buffered saline). The intes-
tines were then incubated at 4 °C in DPBS containing 2
mM EDTA for 30min and in DPBS with 5mM EDTA for
another 30min, shaking the samples in between to separate
the crypts from the connective tissue. Large material was
removed by passing the SN through a 40-μm cell strainer.
One hundred to 200 small intestinal crypts were suspended
in cold liquid Matrigel and incubated at 37 °C for 15min
for Matrigel gelling. Complete ENR medium containing ad-
vanced DMEM/F12 (Sigma), 2mM Glutamax (Invitrogen),
10mM HEPES (Gibco), 100 U/ml penicillin/streptomycin
(Invitrogen), 1mM N-acetyl-cystein (Sigma), B27 supple-
ment (Invitrogen), N2 supplement (Invitrogen), 50 ng/ml
mouse EGF (Peprotech), 100 ng/ml mouse Noggin (Pepro-
tech), and 10% human R-spondin-1-conditioned medium
from R-spondin-1-transfected HEK 293T cells (HA-R-
Spondin1-Fc 293 T stably transfected cell line, expressing
murine Rspo1 with an N-terminal HA epitope tag and
fused to a C-terminal murine IgG2a Fc fragment, obtained
from Dr. Calvin Kuo, details on request) was added to the
cultures. Media were replaced every 2 days. For the orga-
noid passages, after 7 days of culture, Matrigel was mechan-
ically disrupted with a P1000 pipette tip and cold media
were added to help it to liquify. The organoids were broken
into small fragments by pipetting them up and down sev-
eral times using a P200 pipette. Organoid fragments were
pelleted using centrifugation at 465×g for 5min at 4 °C to
wash away the old Matrigel and debris. The organoid frag-
ments were re-suspended in cold liquid Matrigel (50%
Matrigel and 50% complete ENR medium) and reseeded as
described before. After 5 days, organoids were collected for
RNA extraction. For RNA-seq, total RNA was extracted
from ~ 600 organoids using TRIzol reagent (Invitrogen)
and the DNA-free™ DNA Removal kit (ThermoFisher) fol-
lowing the manufacturers’ specifications. Poly(A)+ RNA
was selected using NEBNext Oligo d(T)25 beads (NEB). Li-
braries were prepared with NEBNext Ultra directional
RNA library Prep kit for Illumina (Cat. EZ420S) in combin-
ation with NEBNext Poly(A) mRNA Magnetic Isolation
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Module. Five hundred nanograms of RNA was used with
the fragmentation step at 94 °C for 16min. PCR amplifica-
tion was performed using the KAPA HiFi HotStart PCR kit,
14 cycles.
ChIP-seq
Small intestinal and colon crypts were resuspended in 1ml
of 1% FA/PBS and fixed for 10min at RT. The reaction was
quenched with glycine at a final concentration of 0.125M
for 5min. Cells were pelleted at 2400×g, 4 °C for 2min and
washed three times with 1ml of PBS. Sonication was per-
formed in 180 μl of lysis buffer (50mM Tris-HCl, pH 8.0,
10mM EDTA, 1% SDS, and protein inhibitors cocktail) in
a water-cooled Bioruptor (Diagenode), high power, for 14
cycles with 30 s on and 30 s off. The sonicated chromatin
was diluted in 810 μl of RIPA buffer containing 0.1% SDS
and incubated overnight with protein A/G sepharose Dyna-
beads previously incubated with the specific antibody for
ChIP (H3K9me2—ab1220, and H3K9me3—ab8898
Abcam) for 2 h. For the inputs, 3% of the volume for each
sample was used. Following incubation, the material was
washed 2 times with RIPA low salt buffer (20mM Tris-
HCl, pH 8.0, 2mM EDTA, 150mM NaCl, 1% Triton-X-
100, 0.1% SDS) and 2 times with RIPA buffer high salt
(containing 500mM NaCl) and once with TE buffer (10
mM Tris-HCl, 1mM EDTA). Samples were diluted in
200 μl of elution buffer (20mM Tris-HCl pH 7.5, 5mM
EDTA, and 50mM NaCl) and treated with 2 μl of RNase
(20mg/ml) for 30min at 37 °C. After this treatment, sam-
ples were incubated with proteinase K for 2 h at 65 °C at
300 rpm. The DNA was extracted with phenol-chloroform-
isoamyl alcohol. Library preparation was performed with 5
ng DNA with the NEBNext Ultra II DNA Library Prep for
Illumina, according to the manufacturer’s instructions and
sequenced on the Illumina HiSeq2500 platform, 100 bp
pair-end.
ATAC-seq
Mice were killed, and small intestines extracted, immedi-
ately flushed with ice cold PBS, cut open longitudinally, and
rinsed 3× for 10 s with HBSS (Hank’s balanced salt solu-
tion) without Ca2+/Mg2+. The intestines were incubated 10
min in 30mM EDTA/HBSS on ice, then shaken vigorously
by hand for 5 s and the SN removed. They were incubated
a further 20min in 30mM EDTA/HBSS on ice and then
shaken vigorously for 5min. Villi and mucus were removed
by dripping the material through a 100- then 70-μm
strainer. Crypts were pelleted at 170×g at 4 °C for 10min
and SN removed. The crypts were washed with 10ml ice
cold PBS, re-pelleted, and SN removed, twice. Crypts were
resuspended in 2ml TrypLE Express with 10 μM Y-27632
and 0.5mMN-acetylcysteine, pipetted carefully with a 1-ml
pipet, and dissociated at RT and monitored by microscopy.
The suspension was then topped up with 20ml 10% FBS/
PBS, and the cells were filtered through a 40-μm strainer.
The cell suspension was then pelleted at 465×g, 4 °C for 5
min and resuspended in 5ml ice cold HBSS, twice. The
cells were re-suspended in 2ml 1% Triton-X-100 contain-
ing N-buffer (15mM HEPES, pH 7.5, 10% sucrose, 60mM
KCl, 15mM NaCl, 0.5mM EGTA, 0.2mM PMSF, 1×
Complete™ (Roche) protease inhibitor, 50mM sodium bu-
tyrate) and incubated 15min on ice. This mix was then
overlaid on a 5-ml sucrose cushion (30% sucrose in N-
buffer), and nuclei were pelleted for 15min at 1300×g, 4 °C.
Nuclei were taken up in 100 μl ice cold nuclei storage (25
mM Tris-HCl, pH 7.5, 100mM potassium acetate, 10mM
MgCl2, 2mM Spermidine) and counted. ~ 50,000 cells were
used for each ATAC-seq library as described [43] using the
Nextera kit from Illumina with TruSeq primers. Libraries
were sequenced 50 bp, paired end.
Bioinformatic analysis of ChIP-seq and ATAC-seq data
Reads were adaptor trimmed with Trim Galore (v0.4.4 for
ChIP-seq and v0.4.1 for ATAC-seq) and mapped to the
mouse reference genome GRCm38/mm10 with Bowtie 2
(v2.3.2 for ChIP-seq and v2.2.5 for ATAC-seq). We used
SeqMonk version 1.44.0 for the bioinformatic analysis of
ChIP-seq and ATAC-seq data. For H3K9me2 and
H3K9me3 analysis, we imported paired-end reads as .bam
files with the minimal mapping quality cutoff “20” and
maximal distance 1500 bp cutoff, and duplicates removed
on import. We used MACS peak finder integrated in Seq-
Monk using all ChIP samples and for “input” the input li-
braries from control and KO, fragment size 300,
significance threshold 1 × 10−5. We used EdgeR, embedded
in SeqMonk to identify peaks that change in KO versus
control (WT, p < 0.05 after Benjamini-Hochberg multiple
testing correction). To generate browser shots, we gener-
ated running window probes of 200 bp with 100 bp overlap
and smoothed these further over 5 probes.
For ATAC-seq, we imported .bam files with 1000 bp cut-
off, duplicates removed, quality cutoff “20,” and identified
MACS peaks using SeqMonk with default settings. We used
EdgeR embedded in SeqMonk with significance cutoff p <
0.05 after Benjamini-Hochberg multiple testing correction to
identify peaks that change in KO compared to control (WT).
Microbiome identification
Feces were collected from microbiota donors and WT/
Smarcad1-KO littermates after 28 days of cohousing (as
described above except the DSS supplementation) with
donor mice, which corresponds to a full DSS-induced
colitis experiment timeframe. Two fecal pellets/mouse
were processed by BGI Hong Kong as 250 bp paired-end
read (Illumina) and analysis via the 16S rDNA-amplicon
pipeline. Low-quality and adaptor-polluted reads were
removed prior to paired-end merging to tags. Tags were
assigned to operational taxonomic units (OTU) at 97%
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similarity threshold. Taxonomic ranks were assigned
with the Ribosomal Database Project (RDP) Naïve Bayes-
ian Classifier v.2.2. α- and β-diversity were analyzed
based on OTUs and their taxonomic ranks.
NGS data analysis: RNA-seq sorted cell, colon crypts, SI-
tissue, and SI-organoids
RNA-seq reads were adaptor trimmed with Trim Galore
(v0.4.4, v0.4.2 for organoid and colon crypt data, v0.4.1 for
SI-whole tissue data). Reads were mapped to the mouse ref-
erence genome GRCm38/mm10 with HiSat2 (v2.1.0, no
soft clipping, v2.0.3 for organoid data, v2.0.1 for SI-whole
tissue and colon crypt data). Uniquely mapped RNA-seq
data was analyzed with SeqMonk (v1.43.0, v1.42.0 for orga-
noid, SI-whole tissue, and colon crypt data). Read counts
were quantified over exons of merged transcripts using the
SeqMonk RNA-seq quantitation pipeline. DEG were identi-
fied based on the raw read count quantitation over merged
transcript isoforms with the multiple testing corrected
DESeq2 algorithm in SeqMonk. Fold changes were quanti-
fied after RPKM (Reads Per Kilobase of transcript per Mil-
lion mapped reads) normalization over merged transcript
isoforms in SeqMonk.
NGS data analysis: RNA-seq DSS in colon
RNA-seq reads were mapped to the mouse reference gen-
ome GRCm38/mm10 with HiSat2 (version 2.1.0).
Uniquely mapped RNA-seq data was analyzed with Seq-
Monk version 1.42.0. Read counts were quantified over
exons of merged transcripts using the SeqMonk RNA-seq
quantitation pipeline. As rRNA contamination was de-
tected in 3 samples, rRNA-annotated reads were filtered
(using an rRNA annotation track, submitted with dataset
to GEO). DEG were identified based on the raw read
count quantitation over merged transcript isoforms with
the multiple testing corrected DESeq2 algorithm in Seq-
Monk. Fold changes were quantified after RPKM
normalization over merged transcript isoforms in Seq-
Monk. Gene expression clusters were identified using Seq-
Monk per-probe normalized hierarchical clustering. GO
enrichment analysis of DEG was performed with g:profiler
against the indicated background lists.
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